Molbio Diagnostics IPO: A High-Risk Bet for Long-Term Investors?

Molbio Diagnostics, renowned for its molecular diagnostics solutions, is set to launch an initial public offering (IPO) to raise ₹940 crore. The company aims to channel ₹200 crore into capital expenditures while reducing promoter stake by ₹740 crore through an offer for sale. Post-IPO, the promoter group's share will decrease from 46.6% to 43%.

Expanding Global Reach with Diagnostics Solutions

Founded in 2000, Molbio Diagnostics has established itself as a key player in the diagnostics industry, operating six manufacturing sites in India and catering to over 90 countries. The company’s product portfolio includes the 'Truenat' platform, a portable diagnostic system that delivers results within an hour and is designed for resource-limited settings. This platform is a significant contributor to the company’s revenue, particularly in the area of tuberculosis test kits, which account for 70% of its test kit sales.

Molbio's clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Notably, over half of the company's revenue is generated from its top clients, indicating a high degree of customer concentration.

Financial Performance and Growth Trajectory

Between FY24 and FY26, Molbio Diagnostics reported a 31.5% annual increase in revenue, reaching ₹1,445.7 crore. Net profit saw a 40.2% annual rise, amounting to ₹164.1 crore. The company's EBITDA also grew by 33.2% to ₹328.2 crore, with an EBITDA margin improvement from 22% in FY24 to 22.6% in FY26. In FY26 alone, revenue surged by 41.7%, EBITDA by 27.9%, and net profit by 18.4% year-on-year.

Valuation and Market Position

Post-IPO, Molbio Diagnostics is projected to have a price-earnings (P/E) multiple of up to 57. While direct comparables in the Indian market are absent, peers in the healthcare diagnostics and medical device sectors, such as Poly Medicure and Dr. Lal PathLabs, trade at P/E multiples ranging from 54 to 81.

Despite the promising growth figures, the high P/E ratio suggests a premium valuation, reflecting investor confidence in Molbio's growth potential. However, the concentration of revenue sources and the competitive landscape pose inherent risks. Investors with a high-risk tolerance may find the IPO attractive for potential long-term gains, although careful consideration of market dynamics and Molbio’s strategic initiatives is advised.